BCL2A1 and diffuse large B-cell lymphoma: Previously, the CDK9 inhibitor AZD4573 was shown to lead to reduced MCL1 and BFL1 levels and death of OCI-Ly10 cells and DLBCL patient-derived xenografts in vivo [70].